



Orion Investor presentation

Updated on 26 April 2019

Disclaimer

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

Content



- 1) Orion in brief
- 2) R&D
- 3) Highlights of 1-3/2019
- 4) Outlook and financials
- 5) Businesses
- 6) Sustainability
- 7) Financial calendar



Orion in brief

Key messages

1 Orion develops, manufactures and markets human and animal pharmaceuticals, and APIs. Products marketed in >100 countries.

2 Balanced business model: Both proprietary drugs and generics.



3 Growth targeted through new in-house developed drugs.

4 Core therapy areas in R&D: oncology, CNS and respiratory diseases (Easyhaler family).


5 Strong position in the Nordic generics market.

6 Strong profitability, stable dividends.


Orion at a glance (2018 figures)

	Net sales 977 MEUR
	Operating profit 253 MEUR
	Personnel 3,154
	R&D investments 104 MEUR
	6 production sites in Finland
	Own sales unit in 26 European countries

Sales by business




Sales by market area




On 21 April 2018, Orion signed an agreement on the sale of all shares in Orion Diagnostica Oy (i.e. the Orion Diagnostica business division). Following the transaction, that was completed on 30 April 2018, Orion Diagnostica business is reported as discontinued operation. All figures in this presentation are for continuing operations, if not otherwise stated.

Steady development despite patent expiries

Net sales




Operating profit




On 21 April 2018, Orion signed an agreement on the sale of all shares in Orion Diagnostica Oy (i.e. the Orion Diagnostica business division). Following the transaction, that was completed on 30 April 2018, Orion Diagnostica business is reported as discontinued operation. All figures in this presentation are for continuing operations, if not otherwise stated.

Orion's product mix has changed

Sales by business 2011



Sales by business 2018



■ Proprietary Products


■ Animal Health

■ Contract manufacturing & other

■ Specialty Products

■ Fermion

Net sales, EUR million



Our businesses



Proprietary Products

In-house developed drugs and other drugs with valid product protection



Specialty Products

Generic prescription drugs, OTC and non-medical products, biosimilars



Animal Health

Medicine and well-being products for animals



Fermion


Active pharmaceutical ingredients (APIs)



Contract Manufacturing


Production for other pharmaceutical companies

Orion's strategy - Mission to build well-being




Orion had ~73,000 shareholders on 31 December 2018

By number of shares



- Households (Finnish retail)
- Non-Finnish holders and nominee-registered
- Private corporations
- Public sector
- Non-profit institutions
- Financial and insurance corporations
- Other

By number of votes





Research and development

Focus areas of Orion's R&D




Proprietary products

- Central nervous system
- Oncology
- Respiratory (Easyhaler product family)



Animal Health

- Orion utilises the R&D of proprietary products to develop new medicines for animals.



Fermion

- APIs to Orion's proprietary products
- Generic APIs
- Contract development for pharmaceutical companies

Together we can achieve more in R&D

Research

Early development

Late stage development

Target identification and validation

8–24 mo.

Hit to Lead generation

12–24 mo.

Lead optimisation

18–36 mo.

Candidate selection, preclinical development
12–24 mo.

Phase I

12–14 mo.

Phase II

12–36 mo.

Phase III

18–48 mo.

Collaboration with partners



AsahiKASEI

BUSINESS FINLAND



Collaboration with partners



Orion's key clinical drug development projects

Project	Indication	Phase			Registration
Easyhaler® tiotropium	COPD	Bioequivalence study			
Darolutamide ¹⁾	Prostate cancer (nmCRPC)	I	II	III	
Darolutamide ¹⁾	Prostate cancer (mHSPC)	I	II	III	
ODM-109 (oral levosimendan)	ALS	I	II	III	
ODM-203 (targeted FGFR+VEGFR inhibitor)	Solid tumours	I	II		
ODM-207 (BET protein inhibitor)	Cancer	I			
ODM-208 (CYP11A1 inhibitor)	Prostate cancer (CRPC)	I			
ODM-209 (CYP11A1 inhibitor)	Prostate cancer (CRPC), breast cancer	I			
¹⁾ In collaboration with Bayer					

More information on R&D projects: www.orion.fi/en/rd/orion-rd/pipeline/

 = Completed
 = Ongoing

 = Status changed



**ARAMIS trial: Efficacy
and safety of
darolutamide in non-
metastatic castration-
resistant prostate
cancer**

Orion and Bayer's phase III trial of darolutamide for non-metastatic castration-resistant prostate cancer

- Detailed data presented at the ASCO GU on 14 February 2019 and simultaneously published in the New England Journal of Medicine.
- Darolutamide significantly extended metastasis-free survival with a favourable safety profile compared to placebo.
- The application for marketing authorisation has been submitted in U.S., Japan and EU.
- Bayer is also having discussions with other health authorities regarding the submission for marketing authorisation application.
- Darolutamide has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). If the process proceeds as planned, the sales could in the best-case scenario start in the US already at the end of 2019.
- Phase III ARASENS trial for metastatic prostate cancer continues.


Financial impacts of darolutamide

- **Bayer** has the right to commercialize darolutamide globally.
- **Orion** has the option of co-promoting in Europe. Orion will manufacture the product.
- **Milestone payments** upon first commercial sales:
 - EUR 45 million in the US
 - EUR 20 million in the EU
 - EUR 8 million in Japan
- **Tiered royalties** on product sales
 - Approx. 20%, including production revenue.
- **Potential one-off payments** if certain sales targets are met.




Non-metastatic castration-resistant prostate cancer (nmCRPC)

- A form of prostate cancer associated with rising PSA (Prostate-Specific Antigen) levels despite androgen deprivation therapy (ADT).
- The cancer has not yet spread beyond the prostate region.
- High risk for progression to metastatic disease.
- Until recently, there have been no effective treatment options for this stage. The goal is to achieve disease control without impacting patients' daily lives.



Until recently, there have been no effective treatment options for CRPC patients who have rising Prostate-Specific Antigen (PSA) levels while on ADT and no detectable metastases



Darolutamide has demonstrated low blood-brain barrier penetration that may lead to lower incidence of adverse events

- Darolutamide is a non-steroidal androgen receptor antagonist that binds to the receptor with high affinity and inhibits the growth of prostate cancer cells.
- In preclinical studies, darolutamide has demonstrated low blood-brain barrier penetration.
- This may explain the overall low incidence of central nervous system related adverse events.



ARAMIS Phase III trial design

1,509 patients

Men with nmCRPC currently being treated with ADT, and at high risk for developing metastatic disease

Randomization
2:1

1,200 mg darolutamide + ADT
(600 mg twice a day)
– 955 patients

Placebo twice a day + ADT
– 554 patients

Primary endpoint

- Metastasis-free survival (MFS)

Secondary endpoints

- Overall survival (OS)
- Time to pain progression
- Time to initiation of first cytotoxic chemotherapy
- Time to first symptomatic skeletal event
- Safety and tolerability

Summary of results: Darolutamide shows substantial efficacy and favourable safety profile

- Darolutamide significantly improves metastasis-free survival (MFS):
 - Median 40.4 months with darolutamide vs 18.4 months with placebo
 - Overall improvement of 22 months
- Positive trend in overall survival (OS):
 - 29% reduction in risk of death at interim analysis (P=0.045).
- Darolutamide has a favorable safety profile:
 - It didn't increase rates of critical adverse events (seizures, falls, fractures, rash, cognitive disorder, mental impairment, hypertension) compared to placebo.
 - Only fatigue occurred in >10% of patients.
 - Discontinuation rates similar between darolutamide and placebo.
- Significant benefit over placebo for time to pain progression:
 - 40.3 months vs. with placebo 25.4 months

ARASENS trial continues in order to expand the indication to metastatic prostate cancer

Patients

- Men with metastatic, hormone-sensitive prostate cancer

Treatment

- Darolutamide plus androgen deprivation therapy and six cycles of docetaxel (chemotherapy)

Endpoints

- Primary:
Darolutamide over placebo in overall survival
- Secondary:
Time to castration resistance, time to antineoplastic therapy, time to first symptomatic skeletal event, time to initiation of opioids, time to pain progression, and to characterize the safety and tolerability of darolutamide

Status

- Recruitment finalized, estimated completion of the trial in 2022.

Global prostate cancer estimates (2018)


2nd

most commonly
diagnosed
malignancy
in men worldwide



5th

leading cause of
death from cancer
in men



1.2

million men
diagnosed with
prostate cancer

358,000

died from
the disease



50+

Mainly affects men
over 50, the risk
increases with age

ODM-109: Oral levosimendan for ALS

- First patients recruited in July for the Phase III clinical trial (REFALS).
- By enhancing respiratory muscle function in ALS patients, orally administered levosimendan can help maintain breathing capacity and benefit overall functioning of ALS patients.
- Orion is investing approximately EUR 60 million over three years in the trial.
- The aim is to apply for marketing authorisation in the US and Europe.
- Levosimendan has been granted an Orphan Drug Designation in the US and in the EU.
- It is a molecule originally developed by Orion for the treatment of acute decompensated heart failure. Simdax has been in the market for this indication since 2000.

ODM-109 (ALS): REFALS phase III trial

450 patients

- Levosimendan
1-2mg/day
(300 patients)
- Placebo
(150 patients)

Approx. 100 clinical sites

- US, Canada,
Europe,
Australia

Primary endpoints

- 12 weeks:
Slow vital capacity
(Breathing
capacity compared
to normal subjects)
- 48 weeks:
ALS functional rating
scale (Overall
assessment of
ALS symptoms)

www.clinicaltrials.gov: NCT03505021

ALS (Amyotrophic lateral sclerosis) as a rare disease

1-2/
100,000

Incidence

~16,800

Patients
in the US in 2017

~12,500


Patients
in Europe

~450-500

Patients
in Finland

ODM-208: Pan-steroid hormone synthesis inhibitor (CYP11A1 inhibitor) for castration-resistant prostate cancer

- Steroid hormones stimulate the growth of hormonally regulated cancers, such as most prostate and breast cancers.
- Hormonal treatments are highly effective, but drug resistance will often eventually emerge and cancer will start growing again.
- Preclinical studies have shown that ODM-208 inhibits the synthesis of steroid hormones. It has potential efficacy also for those cancers that have become resistant to the standard hormonal treatments.
- The steroid hormones that are needed and do not promote cancer growth are replaced with additional medication.





Highlights in January-March 2019

Marketing authorisation applications for darolutamide submitted in main markets

1 Marketing authorisation applications for the prostate cancer drug darolutamide submitted in the main markets US, Japan and Europe.

2 Net sales and operating profit were lower than in the comparative period.
R&D expenses increased.
Outlook remains unchanged.



3 Net sales of Proprietary Products slightly declined from the previous year. Easyhaler, Dexdor and Simdax sold well.

Net sales of Specialty Products decreased in Finland and Eastern Europe, but increased in Scandinavia.

4 Orion has launched a Phase I clinical trial on the ODM-209 molecule. This molecule is a selective hormone synthesis inhibitor much like the ODM-208.

Orion will not independently pursue a trial on ODM-104 for Parkinson's disease.

Key strategic target in 2019–2023: Growing more rapidly than the growth in the market

Net sales target
in 2025

1.5

billion EUR

Capital gain from
the sale of Orion
Diagnostics,
EUR 128 million,
supports growth
opportunities.



Own investments in
new clinical trials:

E.g. EUR 60 million
investment in
Phase III trial on ALS
(REFALS).

Investments in sales
and marketing:

E.g. strengthening
the Easyhaler
product family
sales force in Germany.

In-licensing and
product acquisitions:

E.g. reacquisition of
Stalevo sales rights
in Europe.

Investments
supporting growth
estimated
at EUR 30 million
in 2019.

Key figures 1–3/2019

Net sales

241

MEUR (247)
-3%

Operating profit

55

MEUR (70)
-21%

Operating profit
margin

23%



(28%)

Cash flow per share
before financial
items

0.40



EUR (0.39)
+3%

Development of net sales and operating profit




- (1) Product sales without sales margin and product mix change and exchange rate effect
- (2) Product sales margin and product mix change but without exchange rate effect
- (3) Exchange rate effect on gross margin

Geographical breakdown and development of net sales




Net sales by business division

EUR million



1-3/2019



Best-selling pharmaceuticals 1-3/2019

		Indication	Net sales (EUR million)	Change vs 1-3/2018
1.		Asthma, COPD	26	+21%
2.		Parkinson's disease	21	-25%
3.		Intensive care sedative	19	+10%
4.		Acute heart failure	17	+16%
5.		Animal sedatives	10	+15%
6.	Biosimilars 	Rheumatoid arthritis, inflammatory bowel diseases, lymphoma	9	-12%
7.		Inflammatory pain	6	+5%
8.	Divina series 	Menopausal symptoms	5	+8%
9.		Anticoagulant	3	-24%
10.	Generic entacapone products	Parkinson's disease	3	-29%


 = Products of Proprietary Products business division




Proprietary Products

Easyhaler became the top proprietary product


EUR million



1-3/2019



Easyhaler product family will be a key source of growth in the next few years




- Budesonide-formoterol Easyhaler continued strong growth.
- Product family total sales: **+21%**
- Budesonide-formoterol Easyhaler: **+35%**
 - Strong market position in some countries, such as Sweden (market share was 34%* in February).
 - Growth still attainable in certain markets. Investments in sales and marketing made particularly in Germany (market share was 7%* in February).
- Salmeterol-fluticasone sales started in the first European countries in late 2018.
- Development of seventh product, tiotropium, continues.

*) Market shares of sales in EUR.

Orion is taking over the sale of its proprietary Parkinson's drugs in Europe


Sales, EUR million



■ Deliveries of Parkinson's drugs (Stalevo, Comtess/Comtan) to key partners

■ Orion's own sales


Breakdown of sales of Orion's branded Parkinson's drugs by market area




Source: IQVIA, MAT12/2018

Sales of Dexdor intensive care sedative continued to grow - patent expired at the end of March

Sales, EUR million



Total value of European sedatives market:
EUR 569 million (+3%)




Source: IQVIA, MAT 12/2018




Specialty Products




Specialty Products: price competition continued especially in Finland



Net sales by region 1-3/2019



Net sales by product 1-3/2019



In Finland, price competition has led to a decline in the entire market of reference priced prescription drugs

The market of reference priced prescription drugs in Finland (1-3/2019)

MEUR **106** (118)

Market development

-10%



The sales of Orion's reference priced prescription drugs in Finland

MEUR **28** (30)

Orion's development


-7%

Orion is strong in home market Finland

Human pharma market in Finland 1–3/2019

Medicinal and non-medicinal products
in hospital and pharmacy channels: EUR 676 million

EUR million



- Self-care products (pharmacy channel)
- Reference priced prescription drugs (pharmacy channel)

Reference priced prescription drugs

Orion market share in pharmacy

26%
(26%)

Self-care products

Orion market share in pharmacy

24%
(24%)

Human pharmaceuticals total

Orion market share in hospital & pharmacy

11%
(12%)

Orion's key business targets in 2019

1. Preparation for the commercialisation of darolutamide. ARASENS trial (metastatic prostate cancer) continues in order to expand the indication for the molecule.

- Marketing authorisation applications submitted in main markets.
- With recruitment completed, the ARASENS trial continues as planned.

2. Development of orally administered levosimendan (ODM-109) (REFALS) for ALS in phase III clinical trial and preparation for its possible commercialisation.

- Patient recruitment is proceeding as planned

3. Strengthening Orion's position as the most significant provider of generic drugs in Finland. Competitive pricing.

- Orion's sales volume in Finland grew faster than the market.

Orion's key business targets in 2019

4. Competitive product portfolio in Specialty Products and strengthening of product launches.

- Orion's sales volume in Finland grew faster than the market.

5. Accelerating the growth of the Easyhaler product family and strengthening its market position.

Salmeterol-fluticasone launch in Europe.

- Easyhaler product family sales increased by 21 per cent.

6. Evaluation of new in-licensing opportunities in Europe, particularly in the area of hospital care.

- The work continues.



Outlook

Investments in growth EUR 30 million in 2019

- The ongoing projects supporting growth are expected to burden Orion's profit in 2019 by an estimated EUR 30 million.

- This comprises clearly increased depreciation as well as investments in sales and marketing and research.

- At the same time, operating profit is burdened by intense price competition in the market and gradually expanding generic competition for Orion's old proprietary drugs.

Outlook for 2019

Net sales



Orion estimates that in 2019 net sales will be **slightly higher** than in 2018 (net sales in 2018 were EUR 977 million). The estimated net sales include the possible EUR 45 million milestone payment associated with the commercialisation of darolutamide.

Operating profit



Operating profit is estimated to be **at the same level** as in 2018 (operating profit in 2018 was EUR 253 million). The estimated operating profit includes the possible EUR 45 million milestone payment associated with the commercialisation of darolutamide as well as significant investments in actions to generate growth.



Financials

Orion's financial objectives



Growing net sales more rapidly than growth of the pharmaceuticals market. Achievement of this objective requires continuous investment in development of the product portfolio.



Maintaining profitability at a good level. The aim is operating profit that exceeds 25% of net sales.




Keeping the equity ratio at least 50%.




Distributing an annual dividend that in the next few years will be at least EUR 1.30 per share, and increasing the dividend in the long term.


Financial objectives



■ Net sales, EUR million



■ Operating profit, EUR million
 ■ Operating profit margin
 — Target



■ Dividend per share, EUR
 — Target


*) 2016: includes extra dividend EUR 0.20

**) 2018: Board proposal


On 21 April 2018, Orion signed an agreement on the sale of all shares in Orion Diagnostica Oy (i.e. the Orion Diagnostica business division). Following the transaction, that was completed on 30 April 2018, Orion Diagnostica business is reported as discontinued operation. All figures in this presentation are for continuing operations, if not otherwise stated.

Key figures by quarter


Net sales, EUR million




Operating profit, EUR million



Basic earnings per share, EUR



Cash flow per share before financial items*, EUR



On 21 April 2018, Orion signed an agreement on the sale of all shares in Orion Diagnostica Oy (i.e. the Orion Diagnostica business division). Following the transaction, that was completed on 30 April 2018, Orion Diagnostica business is reported as discontinued operation. All figures in this presentation are for continuing operations, if not otherwise stated.

Key figures

Orion's key figures	2013	2014	2015	2016	2017	2018	Change vs. 2017
Net sales, EUR million	1,006.9	1,015.3	1,015.6	1,073.5	1,033.6	977.5	-5.4%
Operating profit, EUR million	267.7	272.4	266.6	314.6	284.1	252.8	-11.0%
Profit before taxes, EUR million	264.0	267.8	262.3	310.9	277.7	248.4	-10.6%
R&D expenses, EUR million	101.9	106.2	108.1	118.2	99.1	104.0	+4.9%
Equity ratio, %	53.6%	52.3%	57.4%	60.8%	64.6%	68.8%	
Gearing, %	8.4%	-4.7%	-9.6%	-12.4%	-1.9%	-17.1%	
ROCE (before taxes), %	38.5%	36.6%	35.7%	40.9%	36.2%	44.3%	
Return on equity, %	40.3%	41.1%	37.5%	40.3%	34.2%	45.5%	
Basic earnings per share, EUR	1.46	1.50	1.48	1.77	1.56	1.40	-10.3%
Cash flow per share before financial items, EUR	1.02	1.72	1.51	1.62	1.09	2.32	+112.4%
Dividend per share, EUR	1.25	1.30	1.30	1.55*	1.45	1.50	+3.4%

*) 2016: dividend includes extra dividend of EUR 0.20

The figures in the table include both continuing and discontinued operations.

Income statement

Formation of profits, EUR million	2013	2014	2015	2016	ADJ.2017	2018	Change vs. 2017
Net sales	1,006.9	1,015.3	1,015.6	1,073.5	1,033.6	977.5	-5.4%
Cost of goods sold	-393.5	-401.7	-405.8	-421.7	-417.6	-387.9	-7.1%
Gross profit	613.4	613.6	609.8	651.8	616.0	589.6	-4.3%
Other operating income and expenses	5.6	1.7	1.5	24.3	4.9	5.5	+10.8%
Sales and marketing expenses	-204.9	-193.4	-190.4	-194.7	-188.9	-195.3	+3.4%
R&D expenses	-101.9	-106.2	-108.1	-118.2	-99.1	104.0	+4.9%
Administrative expenses	-44.5	-43.3	-46.2	-48.7	-48.8	-43.0	-11.8%
Operating profit	267.7	272.4	266.6	314.6	284.1	252.8	-11.0%
Profit before taxes	264.0	267.8	262.3	310.9	277.7	248.4	-10.6%
Profit for the period for continuing operations					219.1	197.3	-9.9%
Profit for the period for discontinued operations					7.0	132.9	
Profit for the period	206.2	211.3	208.2	249.0	226.0	330.3	+46.2%

The figures in the table include both continuing and discontinued operations.

Financial position


EUR million	12/18	12/17	Change %
Non-current assets total	418.5	434.7	-3.7%
Inventories	222.1	225.4	-1.5%
Trade receivables	188.8	199.0	-5.1%
Other receivables	33.7	32.4	+4.0%
Cash & cash equivalents & money market investments	283.7	164.1	+72.9%
Current assets total	728.2	620.8	+17.3%
Assets total	1,146.7	1,055.5	+8.6%

EUR million	12/18	12/17	Change %
Equity total	773.1	679.7	+13.7%
Interest-bearing non-current liabilities	0.6	150.3	-99.6%
Non-current liabilities total	59.8	196.2	-69.5%
Current liabilities total	313.8	179.7	+74.7%
Liabilities total	373.6	375.8	-0.6%
Equity and liabilities total	1,146.7	1,055.5	+8.6%


The consolidated statement of financial position includes both continuing and discontinued operations.

Development of capital expenditure

Orion Capex, EUR million




Development of net working capital



Dividend distribution policy

- Orion's dividend distribution takes into account distributable funds and capital expenditure and other financial requirements in medium and long term to achieve the financial objectives.


EUR Dividend distribution history



2016: includes extra dividend EUR 0.20
2018: Board proposal

Orion B share performance January 2016 - December 2018

Index 31/12/2015=100




Orion B 94.71
 Orion B total return 104.10
 Europe/Pharmaceutical 86.94
 OMXH-Portfolio 107.2



Business units

Proprietary Products: In-house developed prescription drugs with valid product protection

Net sales



Global sales and R&D partner networks



Key drivers:

- ▲ Easyhaler, Simdax
- ▲ Possible milestones
- ▲ New products from R&D pipeline

▼ Generic competition

Proprietary human pharmaceuticals developed by Orion

Product	Indication	Year	 Easyhaler®	Year	Indication
	Sedative for ICU use	2011	Salmeterol-fluticasone Easyhaler®	2018	
	Parkinson's disease	2003	Budesonide-formoterol Easyhaler®	2014	
	Acute decompensated heart failure	2000	Formoterol Easyhaler®	2004	Asthma and COPD
	Sedative for ICU use	1999	Budesonid Easyhaler®	2002	
	Parkinson's disease	1998	Beclomet Easyhaler®	1994	
			Buventol Easyhaler®	1993	
	Breast cancer	1988			

Diverse treatment options for asthma and COPD by utilizing the same inhaler technology

- Easyhaler is a dry-powder inhaler developed in-house
- Orion has developed Easyhaler-adapted dry powder formulations of several well-known generic active substances:
 - salbutamol, beclometasone, budesonide, formoterol, salmeterol and fluticasone
- Key benefits:
 - Dosing accuracy and consistent deposition
 - Easy to teach, learn and use
 - A wide range of products



EASYHALER

Easyhaler product family is expanding

EASYHALER



1984

The idea of Easyhaler is born



1993

Salbutamol Easyhaler



1994

Beclometasone Easyhaler



2002

Budesonide Easyhaler



2004

Formoterol Easyhaler



2014

Bufomix Easyhaler




2018

Salmeterol-Fluticasone Easyhaler

2018

Tiotropium development started

Specialty Products: Generic prescription drugs, biosimilars and OTC including also non-medicinal products



Portfolio of hundreds of products



Animal Health



In-licensed products sold in own sales areas

In-house developed proprietary products sold globally through own sales network and through partners

Medicinal and non-medicinal products for companion animals and livestock

Fermion has an important strategic role



*) Excluding supply to Orion

Active pharmaceutical ingredients (APIs) for Orion's own Proprietary Products



Generic APIs for Orion and other pharma companies

Contract development and manufacturing of APIs

Fermion's new production plant operational in Hanko

- nearly 100% of production is exported

HANKO 2018

**EUR >30
million**

Expansion
investment
2016–2018

**6,000
m²**

Production facility
and equipment
for the production
of APIs

**200->
300 t**

Enables
capacity
increase


~20

Number of APIs
manufactured
at Hanko

- Special expertise in demanding production of active pharmaceutical ingredients (APIs), e.g. extremely potent substances.
- The aim is to captively manufacture the APIs for Orion's in-house developed proprietary drugs, such as darolutamide.
- Modernised, advanced technology at Hanko strengthens Fermion's global competitive position, meets increasingly strict regulatory requirements and provides the means to meet growing demand.
- The Hanko facility manufactures azathioprine and entacapone, among others, in which Fermion is the leading manufacturer globally.

Contract manufacturing & other

EUR million



Pharmaceutical
manufacturing for
other companies





Sustainability is built into Orion's mission

Material themes of Orion's sustainability

- Patient safety
- Ensuring reliable supply of medications
- Manufacturing medications in an environmentally sustainable way: efficient use of materials, energy efficiency, wastewater management

Customer complaints
(Pharmaceuticals)

56

Ppm (64)

Audits undertaken
by Orion

238

(314)

Energy savings

1,074

MWh (3,725)

Energy savings
target set for 2025
achieved

40%

(31%)

Injury rate

5.5

LTIF 1 (6.3)

We assess product safety throughout the lifecycle





Orion calendar

Capital Markets Day

Helsinki, 22 May 2019

Half-Year Financial Report 17/7/2019

Interim Report 1–9/2019 23/10/2019



Investor Relations

Jari Karlson

CFO

jari.karlson@orion.fi

+358 10 426 2883

Heidi Ahti

Executive Assistant

(Investor meeting requests)

heidi.ahti@orion.fi

+358 10 426 2169

www.orion.fi/EN/Investors

twitter.com/OrionCorpIR



Building well-being